Heart disease and heart failure are prevalent issues resulting in thousands of deaths every year. Unfortunately, current treatments do not present viable long-term solutions for heart disease; the only true solution to end-stage heart failure is organ transplant. Unfortunately there is a high demand for organs and an inadequate supply of donor organs available for transplantation. Development of bioengineered cardiac constructs offers an alternative method with functional integration into the body with less possibilities of rejection, thus providing a long-term solution to heart failure/disease. As we continue to develop models for three-dimensional artificial heart muscle (3D-AHM) and other cardiovascular models, it becomes imperative to d...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Disturbances in the propagation of the electrical wavefront can cause cardiac arrhythmia’s that can,...
Heart failure is a leading cause of morbidity worldwide. With no cure, heart transplantation remains...
There is a clear need for improved methods (e.g. computer modelling, imaging) to characterize the su...
Heart disease remains the leading cause of death in the United States, but technology (e.g., pacemak...
The overarching goal of Engineered Heart Tissues (EHTs) is to develop functional 3D heart tissues in...
Drug-induced cardiotoxicity is regarded as a major hurdle in the early stages of drug development. A...
There are the growing interests in microphysiological systems (MPS), also known as organs-on-chips, ...
can bend, stretch and twist. No small feat. Now the flexible and stretchable electronics can map wav...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
There are the growing interests in microphysiological systems (MPS), also known as organs-on-chips, ...
Cardiac tissue engineering has a potential to provide functional, synchronously contractile tissue c...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Disturbances in the propagation of the electrical wavefront can cause cardiac arrhythmia’s that can,...
Heart failure is a leading cause of morbidity worldwide. With no cure, heart transplantation remains...
There is a clear need for improved methods (e.g. computer modelling, imaging) to characterize the su...
Heart disease remains the leading cause of death in the United States, but technology (e.g., pacemak...
The overarching goal of Engineered Heart Tissues (EHTs) is to develop functional 3D heart tissues in...
Drug-induced cardiotoxicity is regarded as a major hurdle in the early stages of drug development. A...
There are the growing interests in microphysiological systems (MPS), also known as organs-on-chips, ...
can bend, stretch and twist. No small feat. Now the flexible and stretchable electronics can map wav...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
There are the growing interests in microphysiological systems (MPS), also known as organs-on-chips, ...
Cardiac tissue engineering has a potential to provide functional, synchronously contractile tissue c...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...